Homepage Top Section1

Under the deal, Merck’s subsidiary will purchase all outstanding shares of Peloton in exchange for an upfront payment of $1.05bn (£825m) in cash. The shareholders of Peloton will

Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of

According to the company, tolimidone significantly reduced HbA1c in comparison to placebo in the mid-stage trial as per the analysis of all patients who were subjected to the

ElevateBio is backed by $150m funding raised through a Series A financing round co-led by the MPM Capital-managed UBS Oncology Impact Fund and F2 Ventures. Other investors in

SEP-363856 was discovered by Sunovion in collaboration with PsychoGenics using the in vivo phenotypic SmartCube platform and the artificial intelligence algorithms associated with it. Its breakthrough therapy designation

As per terms of the agreement, Takeda is also eligible to secure up to an additional $1.9bn in potential milestone payments from Novartis along with $3.4bn upfront payment

The latest approval for Kadcyla is for HER2-positive early breast cancer patients with residual invasive disease after being subjected to neoadjuvant treatment with taxane and Herceptin (trastuzumab). The

Headquartered in California, Abide has developed a platform to discover potent and selective serine hydrolase inhibitors. The platform is used by the company to identify, develop, and validate

Trelegy Ellipta is a once-daily single inhaler triple therapy, which includes fluticasone furoate (FF), umeclidinium (UMEC) and vilanterol (VI). Fluticasone is an inhaled corticosteroid, while umeclidinium is a